| Recruiting | Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC NCT05681780 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Terminated | Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer NCT05617313 | Jeffrey Clarke | Phase 2 |
| Completed | A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) NCT04965090 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During T NCT04878952 | NRG Oncology | N/A |
| Completed | Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer NCT06525246 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemot NCT04623775 | Bristol-Myers Squibb | Phase 2 |
| Terminated | Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab NCT02919449 | Vyriad, Inc. | Phase 1 |
| Completed | Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer NCT02845856 | Fuda Cancer Hospital, Guangzhou | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer NCT02655913 | Clifford Hospital, Guangzhou, China | Phase 1 / Phase 2 |
| Completed | Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuita NCT02262325 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Terminated | Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cance NCT02132884 | Fox Chase Cancer Center | N/A |
| Completed | Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non NCT02243748 | City of Hope Medical Center | N/A |
| Withdrawn | Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-sma NCT02250378 | University of Southern California | N/A |
| Terminated | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung C NCT02134912 | SWOG Cancer Research Network | Phase 2 |
| Completed | Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell NCT01958372 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Recruiting | Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung NCT02178163 | Barbara Ann Karmanos Cancer Institute | N/A |
| Withdrawn | Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer NCT02059889 | Virginia Commonwealth University | N/A |
| Terminated | Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer NCT02145078 | Barbara Ann Karmanos Cancer Institute | N/A |
| Withdrawn | Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient W NCT01928160 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small NCT01784640 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Ch NCT01948141 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cance NCT01824901 | ECOG-ACRIN Cancer Research Group | Phase 1 / Phase 2 |
| Completed | Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients NCT01999881 | University of Wisconsin, Madison | N/A |
| Terminated | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection NCT01249443 | AIDS Malignancy Consortium | Phase 1 |
| Withdrawn | Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Canc NCT02017925 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers NCT01935336 | University of Colorado, Denver | Phase 2 |
| Completed | Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer NCT01839955 | Neelesh Sharma MD PhD | Phase 1 |
| Completed | INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer NCT01911507 | University of California, Davis | Phase 1 |
| Withdrawn | Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cance NCT02126527 | Mayo Clinic | Phase 1 |
| Completed | PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell NCT01723800 | City of Hope Medical Center | Phase 1 |
| Completed | Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung C NCT01781741 | Roswell Park Cancer Institute | EARLY_Phase 1 |
| Completed | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis NCT01806675 | Sanjiv Sam Gambhir | Phase 1 / Phase 2 |
| Completed | Etirinotecan Pegol (NKTR-102) in NSCLC NCT01773109 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Completed | Cognitive Behavioral Therapy in Treating Anxiety in Patients With Stage IV Non-Small Cell Lung Cancer and Thei NCT01729689 | Stanford University | N/A |
| Terminated | Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer NCT01707823 | Vanderbilt-Ingram Cancer Center | EARLY_Phase 1 |
| Terminated | IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors NCT01746810 | New Mexico Cancer Research Alliance | Phase 1 |
| Completed | Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II NCT01649947 | Rutgers, The State University of New Jersey | Phase 2 |
| Terminated | Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot B NCT01411098 | University of Washington | Phase 1 |
| Withdrawn | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer NCT01383668 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination NCT01345851 | Jonsson Comprehensive Cancer Center | N/A |
| Withdrawn | Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body NCT01325753 | Wake Forest University Health Sciences | N/A |
| Terminated | RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment NCT01193868 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors NCT01155258 | University of Southern California | Phase 1 |
| Completed | Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients NCT01026467 | Wake Forest University Health Sciences | — |
| Terminated | Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With NCT00976677 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lun NCT00986674 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC NCT00769600 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small NCT00778167 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell L NCT00652340 | Tragara Pharmaceuticals, Inc. | Phase 2 |
| Completed | AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy NCT00638937 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer NCT02889666 | Shanghai Jiao Tong University School of Medicine | Phase 1 |
| Completed | Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung NCT00499655 | City of Hope Medical Center | Phase 2 |
| Completed | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage NCT01557959 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung C NCT00481078 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer NCT00459342 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec NCT00397384 | National Cancer Institute (NCI) | Phase 1 |
| Completed | E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer NCT00400829 | National Cancer Institute (NCI) | Phase 2 |
| Completed | AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer NCT00410904 | National Cancer Institute (NCI) | Phase 2 |
| Completed | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell L NCT00368992 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer NCT00362882 | National Cancer Institute (NCI) | Phase 2 |
| Completed | AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer NCT00245063 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Ca NCT00408460 | University of Washington | Phase 2 |
| Completed | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Sta NCT00118183 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lu NCT00138203 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer NCT00118144 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors NCT00655655 | Mayo Clinic | Phase 1 |
| Completed | Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer NCT00098540 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer NCT00085280 | National Cancer Institute (NCI) | N/A |
| Completed | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer NCT00087412 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer NCT00093756 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Sma NCT00077350 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or NCT00088933 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191 | National Cancer Institute (NCI) | N/A |
| Completed | Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer NCT00084981 | National Cancer Institute (NCI) | Phase 1 |
| Completed | CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer NCT00079235 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Photodynamic Therapy in Treating Patients With Lung Cancer NCT01668823 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer NCT00075751 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer NCT00062101 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer NCT00088959 | National Cancer Institute (NCI) | Phase 1 |
| Completed | GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-S NCT00074022 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Can NCT00068497 | National Cancer Institute (NCI) | N/A |
| Completed | Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refracto NCT00066768 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Tre NCT00228358 | University of Washington | Phase 1 |
| Completed | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carc NCT00063895 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lun NCT00052338 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurr NCT00021060 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Terminated | Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer NCT00040768 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leuke NCT00039091 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer NCT00029003 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors NCT00028535 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Canc NCT00006929 | National Cancer Institute (NCI) | Phase 2 |
| Completed | FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Can NCT00020202 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER NCT00004883 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |